We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

Keytruda sales account for roughly 40% of Merck’s revenue, and the company has been focused on the 2028 patent expiration for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Merck & Co. Inc. closed $34.98 below its 52-week high ($134.63), which the company achieved on June 25th.